Search

Acute Myeloid Leukemia (AML) Therapeutics Market

Acute Myeloid Leukemia (AML) Therapeutics Market Size by Disease Type (Myelomonocytic, Myeloblastic, and Promyelocytic), Treatment Type [Radiation Therapy, Stem Cell Transplant, Targeted Therapy, and Chemotherapy (Anti-metabolites, Hormonal Therapy, Cytarabine, Alkylating Agents, Tyrosine Kinase Inhibitors, Anthracycline Drugs, and Others)], Regimen (VCD Regimen, DC Regimen, and AVD Regimen), End-user (Hospitals, Ambulatory Care Centres, Clinics and Others), Objectives, Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2022 to 2030

Base Year: 2021 Historical Data: 2019-20
  • Report ID: TBI-12868
  • Published Date: Aug, 2022
  • Pages: 234
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

The global acute myeloid leukemia (AML) therapeutics market is expected to reach USD 2588.23 million by 2030, at a CAGR of 10.62% from 2022 to 2030. The rising incidence of acute myeloid leukemia has called for the developing of effective drugs. Furthermore, the approval of new drugs and rising investments by pharmaceutical giants will lead to the growth of the acute myeloid leukemia therapeutics market. There are a few factors actively contributing to acute myeloid leukemia's growth. Traditional diagnostics are not much efficient and often result in several side effects, including nausea, appetite loss, and tissue damage. Furthermore, the exponential rise in genetic mutations, the geriatric population, and government initiatives to support research will contribute to the global acute myeloid leukemia (AML) therapeutics market in the coming years. The rapid expansion of the acute myeloid leukemia (AML) therapeutic industry will be bolstered in the coming years by the rising deployment of new technologies. Furthermore, the therapeutics industry will also rise, attributed to increasing healthcare expenses.

Market Overview:

Leukemias are tumors that start in cells that ordinarily mature into several blood cell types. Leukemias generally grow in the early development stage of white blood cells, although other types of leukemias begin in other blood cells. Various forms of leukemia are distinguished primarily by whether the leukemia is acute or chronic and whether it starts in lymphoid or myeloid cells. Acute myeloid leukemia begins in the bone marrow; then eventually moves into the blood. It spreads to other body parts, including the spleen, liver, testicles, lymph nodes, and central nervous system. Acute myeloid leukemia (AML) can be life-threatening if not treated properly at the earliest. Acute myeloid leukemia therapeutics include radiation therapy, chemotherapy, targeted therapy, and stem cell transplant. There are different types of chemotherapies utilized for eliminating cancer cells. Modern therapeutics equipment includes several digital systems and thus can detect a broad range of detection.

Get an overview of this study by requesting a free sample

Market Dynamics:

Drivers:
  • Rising incidence of acute myeloid leukemia

The global acute myeloid leukemia (AML) therapeutics market is driven by a rapid increase in acute myeloid leukemia among seniors and people with genetic mutations. Acute myeloid leukemia causes instant in platelets and white blood cells. A person diagnosed with acute myeloid leukemia therapeutics experiences shortness of breath, bleeding, and a higher risk of infection. Around 60,000 cases of acute myeloid leukemia are expected in 2022, of which approximately 24,000 are expected to be in the US alone. The elderly population accounts for a significant percentage of the total patient population. Acute myeloid leukemia has proven to be life-threatening; thus, the demand for associated therapeutics has risen lucratively. The development of AML therapeutics has paved the way for the better treatment of patients.

Restraints:
  • High cost of therapeutics

The high cost of acute myeloid leukemia (AML) therapeutics such as stem cells, radiation, and chemotherapy are restraining market growth. This equipment is costly, and its installation makes it more expensive. These therapeutics use high-tech dug development processes that rely on advanced machinery. Thus, the overall cost of therapeutics rises.

Opportunities:
  • Increasing technological advancements

The rising technological advancements include the development of advanced immunotherapies, which leads to better outcomes and targeted treatment. Many drugs have resurfaced in recent years in most acute myeloid leukemia. There are dozens of drugs in the pipeline and several studies revolving around new therapeutics. Antibodies drugs are being developed for patients who have acute myeloid leukemia. Immune inhibitors technology is being used for the development of such antibodies. Delivery and formulation are also being advanced to be more efficient. The researchers are focusing on understanding genetic mutations to improve molecular technology.

Challenges:
  • Stringent regulations

The launch of therapeutics used for acute myeloid leukemia requires the passing of many global and regional stringent regulations. The manufacturers must pass stringent regulations to launch their drugs on the market. Pharmaceutical agencies have regulations at every step of the pipeline to check the efficacy of the drugs.

Segmentation Analysis:

The global acute myeloid leukemia (AML) therapeutics market has been segmented based on disease type, treatment type, regimen, end-user, and region.

  • The disease-type segment is divided into myelomonocytic, myeloblastic, and promyelocytic. Out of the three main segments, myelomonocytic accounted for 38.84% of the market share in 2021. Myelomonocytic is a more prevalent type of acute myeloid leukemia. It eventually starts in white blood cancer and moves into blood vessels.
  • The treatment type segment is divided into radiation therapy, stem cell transplant, targeted therapy, and chemotherapy. The chemotherapy segment further includes anti-metabolites, hormonal therapy, cytarabine, alkylating agents, tyrosine kinase inhibitors, anthracycline drugs, and others. The chemotherapy segment held the highest share of around 42.67% in 2021. Chemotherapy is one of the most widely used treatments in acute myeloid leukemia therapeutics. Chemotherapy is effective in the removal of cancer cells to a greater extent.
  • The regimen segment is divided into VCD, DC, and AVD regimens. Out of these technologies, the VCD regimen accounted for 37.90% of market shares in 2021. VCD regimen is preferable for patients diagnosed with acute myeloid leukemia therapeutics. It induces effective partial responses, as most patients can easily tolerate it.
  • The end-user segment is divided into hospitals, ambulatory care centers, clinics, and others. In 2021, hospitals accounted for 46.32% of the market revenue. Hospitals have higher incoming patients suffering from acute myeloid leukemia. The therapeutics used for treating such leukemia are mainly utilized in hospitals. Hospitals invest hugely in acute myeloid leukemia therapeutics and thus contribute hugely to the segment.
Regional Segmentation Analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North American region emerged as the largest market for the global acute myeloid leukemia (AML) therapeutics market, with a 39.19% market revenue share in 2021.

  • In 2021, the acute myeloid leukemia (AML) therapeutics market was dominated by North America because of significant technological advancements in the current therapeutics, a well-established healthcare infrastructure, and a strong emphasis on research and development of the leukemia industry.
  • In addition, the Asia Pacific region will have the fastest CAGR in the market. The rising awareness of advanced therapeutics and increased R&D spending on acute myeloid leukemia (AML) therapies will benefit the region's market size.

North America Region Acute Myeloid Leukemia (AML) Therapeutics Market Share in 2021 - 39.19%

 

www.thebrainyinsights.com

Check the geographical analysis of this market by requesting a free sample

Competitive Analysis:

The key players are now concentrating on implementing strategies such as adopting new technology, product innovations, mergers & acquisitions, joint venture, alliances, and partnerships to improve their market position in the global acute myeloid leukemia (AML) therapeutic industry.

In January 2022, a significant player, Oncolyze Inc., received orphan drug designation by the FDA; their pipeline compound, OM-301, was developed for treating acute myeloid leukemia.

List of Key Market Players:

  • Cephalon Inc
  • Novartis AG
  • Celgene Corporation
  • Pfizer Inc.
  • Eisai Co. Ltd
  • Bristol Myers Squibb
  • Eli Lilly and Company
  • Sunesis Pharmaceuticals Danaher Corporation
  • Otsuka Holdings Co. Ltd.
  • Genzyme Corporation
  • Takeda Pharmaceuticals
  • Ambit Biosciences Corporation

Key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities
  • Consulting And Research Firm

Report Description:

  • Global Acute Myeloid Leukemia (AML) Therapeutics Market, Industry Analysis, Trends, Analysis and Forecast, 2022 to 2030, is a forthcoming/imminent research report for publication by The Brainy Insights.
  • 2021 is considered the base year of the report. 2019 and 2020 are considered historical years, and 2022 to 2030 are forecast years. The global acute myeloid leukemia (AML) therapeutics market is based on revenue (USD Million). The report incorporates the market study based on revenue. The study covers the market share revenue/market share/volume for each of the segments, regions, and countries catering to the global acute myeloid leukemia (AML) therapeutics market. The regions analyzed for the market are Europe, Asia Pacific, North America, South America, and Middle East & Africa. Furthermore, the regions are further analyzed at the country level.
  • The report encompasses the relative data & information, which have been validated by the leading industry professionals and experts across the globe. The research report also delivers an outline of the attractiveness of acute myeloid leukemia (AML) therapeutics based on disease type, treatment type, regimen, end-user, and regions which are deduced and formulated based on their growth rate (CAGR), market size, and attractiveness by analyzing the present and prospects to fathom market growth and development in future.
  • The report illustrates the detailed (both quantitative and qualitative) analysis of historical data, revenues, and key developments, along with the crucial strategies adopted by key organizations catering to the global acute myeloid leukemia (AML) therapeutics market. This offers vital and in-depth insights to depict the overall market scenario.
  • The report offers a detailed study of the company profiles of key organizations operating in the global acute myeloid leukemia (AML) therapeutics market and a comparative assessment based on their product offering, business overviews, geographic presence, business strategies, segment market share, product development & innovations, recent developments, joint venture, partnerships, mergers & acquisitions, strategic alliances, SWOT analysis, and key financial information. This helps in evaluating the overall competition present in the market scenario.
  • The report provides an elaborative assessment of porter's five forces analysis coupled with SWOT analysis to provide business-related data and information. Porter's five forces model is analyzed to understand the overall competitive scenario that is prevailing in the market. Additionally, the SWOT analysis identifies both the positive and negative attributes of the market development, which influences the company's growth and development to sustain and survive in the long run.
  • Along with that, the report also focuses on the market-related driving factors, growth limitations (restraints), potential industry opportunities, significant trends, and development which act as a key potential for the investors.
  • Potential growth prospects, along with the penetration rate analysis of the product (market related, i.e., global acute myeloid leukemia (AML) therapeutics market), are covered to comprehend the adoption rate and evaluate the market size. 

Frequesntly Asked Questions

As per The Brainy Insights, the size of the acute myeloid leukemia (AML) therapeutics market was valued 1043.52 million in 2021 to USD 2588.23 million by 2030.

Global acute myeloid leukemia (AML) therapeutics market is growing at a CAGR of 10.62% during the forecast period 2022-2030.

The global acute myeloid leukemia (AML) therapeutics market has been segmented based on disease type, treatment type, regimen, end-user, and regions. The myelomonocytic segment led the market in 2021

North America region emerged as the largest market for the acute myeloid leukemia (AML) therapeutics.

The market's growth will be influenced by the rising cases of acute myeloid leukemia due to genetic mutations.

The high cost of therapeutics could hamper the market growth.

The rising technological advancements provide huge opportunities to the market.

Key players are Cephalon Inc., Novartis AG, Celgene Corporation, Pfizer Inc., Eisai Co. Ltd, Bristol Myers Squibb, Eli Lilly and Company, Sunesis Pharmaceuticals Danaher Corporation, Otsuka Holdings Co. Ltd., Genzyme Corporation

Get Your Report Customized

  • Further segmentation of the market on the basis of type, application, end use, product, technology, method, process and any other segment depending on the market
  • Segmentation on the basis of any specific country or region
  • Any segment can be classified on the basis of application
  • Application segment can be further divided on the basis of companies
  • The companies profiled are not limited, we can incorporate additional companies of your choice
  • We can split the company market share on the basis of product, application and region
  • Report can be prepared for any specific country/region/segment
  • Customers can be added on the basis of regions and countries
Request for Customization

1. Introduction
    1.1. Regimen of the Study
    1.2. Market Definition
    1.3. Research Scope
    1.4. Currency
    1.5. Key Target Audience

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
    4.1. Porter’s Five Forces Analysis
    4.2. Value Chain Analysis
    4.3. Top Investment Pockets
          4.3.1. Market Attractiveness Analysis By Disease Type
          4.3.2. Market Attractiveness Analysis By Treatment Type
          4.3.3. Market Attractiveness Analysis By Regimen
          4.3.4. Market Attractiveness Analysis By End-user
          4.3.5. Market Attractiveness Analysis By Region
    4.4. Industry Trends

5. Market Dynamics
    5.1. Market Evaluation
    5.2. Drivers
          5.2.1. Increasing cases of acute myeloid leukemia
    5.3. Restraints
          5.3.1. High cost of therapeutics
    5.4. Opportunities
          5.4.1. Increasing technological advancements
    5.5. Challenges
          5.5.1. Stringent regulations

6. Global Acute Myeloid Leukemia (AML) Therapeutics Market Analysis and Forecast, By Disease Type
    6.1. Segment Overview
    6.2. Myelomonocytic
    6.3. Myeloblastic
    6.4. Promyelocytic

7. Global Acute Myeloid Leukemia (AML) Therapeutics Market Analysis and Forecast, By Treatment Type
    7.1. Segment Overview
    7.2. Radiation Therapy
    7.3. Stem Cell Transplant
    7.4. Targeted Therapy
    7.5. Chemotherapy
          7.5.1. Anti-Metabolites
          7.5.2. Hormonal Therapy
          7.5.3. Cytarabine
          7.5.4. Alkylating Agents
          7.5.5. Tyrosine Kinase Inhibitors
          7.5.6. Anthracycline Drugs
          7.5.7. Others

8. Global Acute Myeloid Leukemia (AML) Therapeutics Market Analysis and Forecast, By Regimen
    8.1. Segment Overview
    8.2. VCD Regimen
    8.3. DC Regimen
    8.4. AVD Regimen

9. Global Acute Myeloid Leukemia (AML) Therapeutics Market Analysis and Forecast, By End-user
    9.1. Segment Overview
    9.2. Hospitals
    9.3. Ambulatory Care Centres
    9.4. Clinics
    9.5. Others

10. Global Acute Myeloid Leukemia (AML) Therapeutics Market Analysis and Forecast, By Regional Analysis
    10.1. Segment Overview
    10.2. North America
          10.2.1. U.S.
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Europe
          10.3.1. Germany
          10.3.2. France
          10.3.3. U.K.
          10.3.4. Italy
          10.3.5. Spain
    10.4. Asia-Pacific
          10.4.1. Japan
          10.4.2. China
          10.4.3. India
    10.5. South America
          10.5.1. Brazil
    10.6. Middle East and Africa
          10.6.1. UAE
          10.6.2. South Africa

11. Global Acute Myeloid Leukemia (AML) Therapeutics Market-Competitive Landscape
    11.1. Overview
    11.2. Market Share of Key Players in the Acute Myeloid Leukemia (AML) Therapeutics Market
          11.2.1. Global Company Market Share
          11.2.2. North America Company Market Share
          11.2.3. Europe Company Market Share
          11.2.4. APAC Company Market Share
    11.3. Competitive Situations and Trends
          11.3.1. Product Launches and Developments
          11.3.2. Partnerships, Collaborations, and Agreements
          11.3.3. Mergers & Acquisitions
          11.3.4. Expansions

12. Company Profiles
    12.1. Cephalon Inc.
          12.1.1. Business Overview
          12.1.2. Company Snapshot
          12.1.3. Company Market Share Analysis
          12.1.4. Company Product Portfolio
          12.1.5. Recent Developments
          12.1.6. SWOT Analysis
    12.2. Novartis AG
          12.2.1. Business Overview
          12.2.2. Company Snapshot
          12.2.3. Company Market Share Analysis
          12.2.4. Company Product Portfolio
          12.2.5. Recent Developments
          12.2.6. SWOT Analysis
    12.3. Celgene Corporation
          12.3.1. Business Overview
          12.3.2. Company Snapshot
          12.3.3. Company Market Share Analysis
          12.3.4. Company Product Portfolio
          12.3.5. Recent Developments
          12.3.6. SWOT Analysis
    12.4. Pfizer Inc.
          12.4.1. Business Overview
          12.4.2. Company Snapshot
          12.4.3. Company Market Share Analysis
          12.4.4. Company Product Portfolio
          12.4.5. Recent Developments
          12.4.6. SWOT Analysis
    12.5. Eisai Co. Ltd
          12.5.1. Business Overview
          12.5.2. Company Snapshot
          12.5.3. Company Market Share Analysis
          12.5.4. Company Product Portfolio
          12.5.5. Recent Developments
          12.5.6. SWOT Analysis
    12.6. Bristol Myers Squibb
          12.6.1. Business Overview
          12.6.2. Company Snapshot
          12.6.3. Company Market Share Analysis
          12.6.4. Company Product Portfolio
          12.6.5. Recent Developments
          12.6.6. SWOT Analysis
    12.7. Eli Lilly and Company
          12.7.1. Business Overview
          12.7.2. Company Snapshot
          12.7.3. Company Market Share Analysis
          12.7.4. Company Product Portfolio
          12.7.5. Recent Developments
          12.7.6. SWOT Analysis
    12.8. Sunesis Pharmaceuticals
          12.8.1. Business Overview
          12.8.2. Company Snapshot
          12.8.3. Company Market Share Analysis
          12.8.4. Company Product Portfolio
          12.8.5. Recent Developments
          12.8.6. SWOT Analysis
    12.9. Otsuka Holdings Co. Ltd.
          12.9.1. Business Overview
          12.9.2. Company Snapshot
          12.9.3. Company Market Share Analysis
          12.9.4. Company Product Portfolio
          12.9.5. Recent Developments
          12.9.6. SWOT Analysis
    12.10. Genzyme Corporation
          12.10.1. Business Overview
          12.10.2. Company Snapshot
          12.10.3. Company Market Share Analysis
          12.10.4. Company Product Portfolio
          12.10.5. Recent Developments
          12.10.6. SWOT Analysis
    12.11. Takeda Pharmaceuticals
          12.11.1. Business Overview
          12.11.2. Company Snapshot
          12.11.3. Company Market Share Analysis
          12.11.4. Company Product Portfolio
          12.11.5. Recent Developments
          12.11.6. SWOT Analysis
    12.12. Ambit Biosciences Corporation
          12.12.1. Business Overview
          12.12.2. Company Snapshot
          12.12.3. Company Market Share Analysis
          12.12.4. Company Product Portfolio
          12.12.5. Recent Developments
          12.12.6. SWOT Analysis
 

List of Table

1. Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

2. Global Myelomonocytic, Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million) 

3. Global Myeloblastic, Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million) 

4. Global Promyelocytic, Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million) 

5. Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

6. Global Radiation Therapy, Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million) 

7. Global Stem Cell Transplant, Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million) 

8. Global Targeted Therapy, Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million) 

9. Global Chemotherapy, Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million) 

10. Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million) 

11. Global VCD Regimen, Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million) 

12. Global DC Regimen, Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million) 

13. Global AVD Regimen, Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million)

14. Global Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

15. Global Hospitals, Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million) 

16. Global Ambulatory Care Centres, Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million) 

17. Global Clinics, Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million) 

18. Global Others, Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million) 

19. Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Region, 2019-2030 (USD Million) 

20. North America Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

21. North America Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

22. North America Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million) 

23. North America Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

24. U.S. Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

25. U.S. Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

26. U.S. Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million) 

27. U.S. Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

28. Canada Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

29. Canada Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

30. Canada Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million) 

31. Canada Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

32. Mexico Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

33. Mexico Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

34. Mexico Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million)

35. Mexico Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

36. Europe Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

37. Europe Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

38. Europe Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million)

39. Europe Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

40. Germany Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

41. Germany Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

42. Germany Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million) 

43. Germany Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

44. France Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

45. France Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

46. France Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million)

47. France Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

48. U.K. Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

49. U.K. Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

50. U.K. Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million)

51. U.K. Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

52. Italy Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

53. Italy Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

54. Italy Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million)

55. Italy Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

56. Spain Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

57. Spain Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

58. Spain Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million) 

59. Spain Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

60. Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

61. Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

62. Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million) 

63. Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

64. Japan Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

65. Japan Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

66. Japan Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen 2019-2030 (USD Million)

67. Japan Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

68. China Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

69. China Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

70. China Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million)

71. China Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

72. India Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

73. India Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

74. India Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million) 

75. India Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

76. South America Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

77. South America Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

78. South America Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million) 

79. South America Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

80. Brazil Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

81. Brazil Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

82. Brazil Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million) 

83. Brazil Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

84. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

85. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

86. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million)

87. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

88. UAE Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

89. UAE Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

90. UAE Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million)

91. UAE Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

92. South Africa Acute Myeloid Leukemia (AML) Therapeutics Market, By Disease Type, 2019-2030 (USD Million) 

93. South Africa Acute Myeloid Leukemia (AML) Therapeutics Market, By Treatment Type, 2019-2030 (USD Million) 

94. South Africa Acute Myeloid Leukemia (AML) Therapeutics Market, By Regimen, 2019-2030 (USD Million) 

95. South Africa Acute Myeloid Leukemia (AML) Therapeutics Market, By End-user, 2019-2030 (USD Million) 

List of Figures 

1. Global Acute Myeloid Leukemia (AML) Therapeutics Market Segmentation

2. Acute Myeloid Leukemia (AML) Therapeutics Market: Research Methodology

3. Market Size Estimation Methodology: Bottom-Up Approach

4. Market Size Estimation Methodology: Top-Down Approach

5. Data Triangulation

6. Porter’s Five Forces Analysis 

7. Value Chain Analysis 

8. Global Acute Myeloid Leukemia (AML) Therapeutics Market Attractiveness Analysis By Disease Type

9. Global Acute Myeloid Leukemia (AML) Therapeutics Market Attractiveness Analysis By Treatment Type

10. Global Acute Myeloid Leukemia (AML) Therapeutics Market Attractiveness Analysis By Regimen

11. Global Acute Myeloid Leukemia (AML) Therapeutics Market Attractiveness Analysis By End-user

12. Global Acute Myeloid Leukemia (AML) Therapeutics Market Attractiveness Analysis By Region

13. Global Acute Myeloid Leukemia (AML) Therapeutics Market: Dynamics

14. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Disease Type (2022 & 2030)

15. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Treatment Type (2022 & 2030)

16. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Regimen (2022 & 2030)

17. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by End-user (2022 & 2030)

18. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Regions (2022 & 2030)

19. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Company (2021)

This study forecasts revenue at global, regional, and country levels from 2019 to 2030. The Brainy Insights has segmented the global acute myeloid leukemia (AML) therapeutics market based on below mentioned segments:

Global Acute Myeloid Leukemia (AML) Therapeutics Market by Disease Type:

  • Myelomonocytic
  • Myeloblastic
  • Promyelocytic

Global Acute Myeloid Leukemia (AML) Therapeutics Market by Treatment Type:

  • Radiation Therapy
  • Stem Cell Transplant
  • Targeted Therapy
  • Chemotherapy
    • Anti-Metabolites
    • Hormonal Therapy
    • Cytarabine
    • Alkylating Agents
    • Tyrosine Kinase Inhibitors
    • Anthracycline Drugs
    • Others

Global Acute Myeloid Leukemia (AML) Therapeutics Market by Technology:

  • VCD Regimen
  • DC Regimen
  • AVD Regimen  

Global Acute Myeloid Leukemia (AML) Therapeutics Market by End-user:

  • Hospitals
  • Ambulatory Care Centres
  • Clinics
  • Others

Global Acute Myeloid Leukemia (AML) therapeutics Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Ask for customization Request Sample Speak to analyst Inquire before buying

Flexible Purchase Options

  • Chapters of your choice
  • Quantitative Information for Historical & Forecasted Data
  • Regional/Country Level Reports
Request for Special Pricing

Get in touch with us

+1-315-215-1633

sales@thebrainyinsights.com

Our Clients

Why choose us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date